NCT02577120
Wound Healing Endpoint and Recurrence
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 14 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 11 words Show 7 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Feb 2029 to May 31, 2023
- Enrollment target: estimated 100 to confirmed 106
- Study completion date changed from estimate of Feb 2034 to Dec 16, 2025
- Study description revised
- Site details revised at 3 of 3 sites
- Publications: details revised at 20 of 21 entries
- Notable Trial status: Suspended to Active, Not Recruiting
- Collaborators shortened, about 6 words
Notable Phase: Phase 4 to Phase 1/2v13 Show 10 more changesShow less
- Lead sponsor: Indiana University to Sashwati Roy
- Enrollment target: 265 to 100
- Primary completion date: Feb 2025 to Feb 2029
- Eligibility criteria expanded, about 13 words
- Primary endpoints: 2 to 1
- Study sites: 1 to 3
- Study completion date: Feb 2025 to Feb 2034
- Interventions: Ceramiseal (Biological), Epiceram Skin Barrier Function (Device), Vaseline Petroleum Jelly (Biological) to Epiceram Skin Barrier Function (Device), Vaseline Petroleum Jelly (Biological)
- Study description shortened, about 577 words
- Study arms: 5 to 2
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: The study is temporarily suspended as the PI works to transfer the study to her new institution.
- Primary and study completion dates: Dec 2023 to Feb 2025
- Start date: Jan 9, 2019 to Jan 8, 2019
- Site details revised
- Notable Phase: Not specified to Phase 4
- Site contact updated
Show 8 earlier versionsHide 8 earlier versions
- Minor Site contact updatedv9
- Notable Primary and study completion dates: Dec 2020 to Dec 2023
- Start date: Jan 15, 2019 to Jan 9, 2019
- Notable Eligibility criteria expanded, about 16 words
- Study description expanded, about 14 words
- Site contact updated
- Minor Start date changed from estimate of Jan 30, 2019 to Jan 15, 2019v6
- Notable Lead sponsor: Ohio State University to Indiana University
- Primary and study completion dates: Dec 2018 to Dec 2020
- Start date: May 2015 to Jan 30, 2019
- Study sites: 2 to 1
- Minor Site contacts updated at 2 of 2 sitesv4
- Minor Site details revised at 2 of 2 sitesv3
- Notable Eligibility criteria expanded, about 42 words
- Study description expanded, about 21 words
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
Devices: Epiceram Skin Barrier Function
Biologicals: Vaseline Petroleum Jelly
Sites
3 sites in 1 country